Cytodyn Inc (CYDY)

[tonysd57]

Here's what I would suggest if shareholders want to spend time reaching out to media, I've been on Twitter for about three weeks and probably sent 200 tweets to big name politicians, celebrities, investment writers, etc- it's pretty much been a waste of time, just get lost in the maze/morass of Twitter world

So I would suggest you pick a handful of news print writers, LA Times, SF Chronicle, Atlanta, Dallas etc and keep hammering away at them. Also say thanks & recognize the few that have mentioned us. This strategy has worked for me & I've been exchanging information with Lisa Krieger of Bay Area News Group at [e-mail]

And Peter Fimrite at San Francisco Chronicle [e-mail] I always copy/paste recent press release or video presentations

Also just sent a thank you with information to Aristos Georgiou of Newsweek Magazine who did a piece on us today at [e-mail]

Hello Aristos:

Appreciate the piece on Cytodyn, Inc which continues to fly well below mainstream national news media outlets, your one of a very few that has recognized them. They are well ahead of others in the race for a treatment and now have doctors/hospitals across the country clamoring for the monoclonal antibody Leronlimab.

It’s the ONLY DRUG working in the ICU and saving lives, often in astonishingly quick fashion. Now in west coast hospitals and sharing patient data as soon as it’s available. The FDA is very familiar with the drug having seen the fantastic safety/efficacy in 850+ HIV, Cancer & GVHD patients- Thats why they don’t hesitate to approve it for Emergency use, they know wit does NO harm, and invariably is the cure ( 92% - 95% in HIV) for whatever it attacks.

Attaching a recent press release- Many more can be found at company website. Again, appreciate the coverage and very best to you & yours as we all grapple with the pandemic.


https://content.equisolve.net/_db373f8119150c85817ed8f616297d92/cytodyn/news/2020-04-09_Blood_Samples_at_Day_0_3_and_7_for_Severely_Ill_413.pdf

www.cytodyn.com CEO Dr. Nadar Pourhassan [e-mail]